Pfister et al. reported that in preclinical models of NASH-induced HCC, immunotherapy against PD-1 increased the number of CD8+PD-1+ T cells within tumors but it did not lead to tumor regression thus suggesting that immune surveillance was impaired [50]. The gene discussed is PDCD1; the disease is neoplasm.